Bellisio Foods, one of the nation's largest, most trusted and fastest growing frozen food companies, introduces SO RIGHT®, a line of single-serve frozen meals that combine real ingredients and great flavors at a truly affordable price.
SO RIGHT meals offer so much of what consumers crave. They feature fresh-tasting, quality ingredients, like 100 percent natural white meat chicken (minimally processed with no artificial ingredients), roasted vegetables, whole grains, and brown rice. In addition, all of the meals are free of trans fats, high fructose corn syrup, and artificial flavors or colors, and contain 11 grams of protein or more; and many of the meals have 300 calories or less, 10 or fewer grams of total fat, and no preservatives.
To view the multimedia release go to:
https://www.multivu.com/players/English/8102351-bellisio-foods-so-right-single-serve-frozen-meals/
Nearly 12 million men in the U.S. suffer from symptoms related to benign prostatic hyperplasia (BPH), an enlargement of the prostate that can cause issues such as frequent and weak urinary streams and sleep deprivation from getting up repeatedly during the night to urinate. Since traditional BPH therapies such as daily medications and more invasive or surgical procedures often result in unwanted side effects and complications, more than 54 percent of men who would benefit from treating their BPH choose not to do anything1. With today’s national introduction of the FDA-cleared Rezūm® System, NxThera provides urologists and their patients suffering from symptomatic BPH with a new, safe and effective minimally-invasive, office-based treatment option which improves quality of life and preserves sexual function2 – one of the main reasons many men choose to forego medications or more invasive procedures.
“Men suffering from BPH are constantly evaluating the trade-offs between maintaining their current declined quality of life or treating their BPH symptoms and possibly incurring long term side effects,” said Dr. Kia Michel, M.D., a urologist at Comprehensive Urology in Los Angeles who recently performed the procedure as part of a nationally televised segment on prostate health. “Of all the minimally-invasive BPH treatments I’ve performed, Rezūm is the most effective and most versatile treatment available to patients – and the results have been excellent.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7933151-nxthera-rezum-therapy/
Following FDA approval of the AspireSR® generator for the VNS Therapy® system in June 2015, more than a thousand patients with drug-resistant epilepsy across the United States have received this new treatment option. Many of these patients are experiencing benefits which have positively impacted their lives – and are sharing their stories during Epilepsy Awareness Month with the hope of encouraging others to seek new treatments for drug-resistant epilepsy. Numerous hospitals nationwide have begun providing the AspireSR device to patients with drug-resistant epilepsy – a condition that affects as many as one-third of people with epilepsy, causing them to have seizures in spite of treatment with antiepileptic medications.
The VNS Therapy system is a minimally invasive option in which a medical device is placed under the skin in the upper chest area during an outpatient procedure. The device sends mild electrical pulses through the vagus nerve to areas of the brain known to be associated with seizures. The new AspireSR generator takes the VNS Therapy technology a step further – detecting relative heart-rate increases that are often associated with seizures in people with epilepsy and providing responsive stimulation in an attempt to stop and shorten seizures and improve recovery.
To view the multimedia release go to:
http://www.multivu.com/players/English/7651751-livanova-aspiresr-treatment/
Brooklyn-based Victoria Fine Foods, the top-selling slow kettle cooked pasta sauce manufacturer in the U.S., announces today that it will expand distribution this month in more than 400 cities across Florida and California. In total, nearly 2,500 stores across Florida and southern California will stock the company’s premium line of kettle-cooked pasta sauces by the end of the month. Suggested retail price for Victoria’s premium line of pasta sauces range from $7.99 - $8.99 per 24-ounce jar.
Victoria’s growth is, in part, a reflection of growing consumer interest in better-for-you, minimally-processed foods; a trend that fits the company’s core ingredients-first approach. In fact, since its inception in 1929 the company has used only fresh, real food ingredients that are kettle-cooked in small batches to provide a true homemade sauce in ready-to-eat form.
To celebrate its new availability in California and Florida, Victoria has launched a recipe contest to identify the best pasta dish in each new region. Participants can enter simply by uploading a photo of their favorite pasta recipe using the hashtag #Pastaratzzi for a chance to win a $1,000 kitchenware makeover and other prizes. For contest details, visit www.Facebook.com/VictoriaFineFoods.
To view the multimedia release go to:
http://www.multivu.com/players/English/7630151-victoria-fine-foods-expansion/
Invuity, Inc. (NASDAQ:IVTY), an advanced medical technology company, announced today the launch of its Hidden ScarTM Surgery program designed to certify surgeons and establish Centers of Excellence at major cancer centers and hospitals across the country. This innovative program will train surgeons on advanced minimally invasive and minimal access surgical approaches that deliver optimal clinical and aesthetic outcomes for patients. As part of the company’s broader women’s health initiative, Invuity is hosting a Hidden Scar Breast Cancer Surgery training course in advance of the American College of Surgeons (ACS) Clinical Congress.
Invuity aims to transform the surgical treatment of breast cancer with this advanced surgical approach for nipple sparing mastectomies and lumpectomies (breast conserving surgery). Hidden Scar Breast Cancer Surgery expands surgical options for patients, offering superior cosmetic outcomes that can improve their psychological and emotional recovery and enhance quality of life after surgery.1
With growing demand for less invasive alternatives to breast cancer surgery, surgeons need to operate through smaller incisions with limited fields of vision. Invuity’s illumination technology allows surgeons to access and visualize the entire breast cavity through discrete incision locations, enabling surgeons to safely and effectively treat breast cancer while preserving the natural shape of the breast and thereby minimizing and hiding the scars.
To view the multimedia release go to:
http://www.multivu.com/players/English/7644051-invuity-hidden-scar-breast-cancer-surgery-program/
The Alfred Mann Foundation (AMF) today announced the first subject, a U.S. Marine, SSgt James Sides, as a recipient of its highly anticipated IMES System (implantable myoelectric sensor) – an experimental system that holds the promise of being the first minimally invasive, intuitive, multi-channel control system for prosthetics intended for long term use. The IMES System is currently being studied under the Investigational Device Exemption (IDE) regulations of the U.S. Food and Drug Administration (FDA). AMF’s ongoing trial with injured veterans at the Walter Reed National Medical Military Center anticipates subjects intuitively operating three different prosthetic movements simultaneously: opening and closing the hand, rotating the wrist, and moving the thumb. Combining these three movements enables several grasps that are invaluable for performing everyday tasks.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65112-alfred-mann-foundation-u-s-marine-subject-fda-study-for-imes-system
Bone and Joint Center is a center of hip excellence for arthroscopic surgery of sports-related injuries, FAI, hip impingement, ACL, labral tears and also minimally invasive anterior approach total hip replacement.
Prem Rabindranauth, MD, a heart surgeon at Gundersen Lutheran Health System in La Crosse, Wis., is using an exciting technique, called minimally invasive coronary surgery (MICS), to perform heart bypass surgery. To perform MICS, a very small three-inch cut is made between the ribs instead of the long cut through the breast bone that is needed with traditional open heart surgery. This means less pain and blood loss, fewer risks for problems, shorter hospital stays and quicker healing time.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/gundluth/49124/
Hologic, Inc. (Hologic or the Company) (Nasdaq: HOLX), a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today celebrates 10 years of the availability and success of its NovaSure endometrial ablation system. Since 2001, more than one and a half million women have been treated with the NovaSure system to reduce or eliminate their heavy periods, without the need to undergo hysterectomy. The NovaSure procedure is a one-time, five-minute procedure that can be performed in the doctor’s office with very minimal recovery time.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/hologic/50096/
Many children and teens suffering from tachycardia, or rapid heart rate, have relied on medication to regulate their heart rhythms and control symptoms such as fatigue, dizziness and fainting spells. However, doctors at the Akron Children’s Hospital Arrhythmia Center have made great strides in curing tachycardia with minimally invasive procedures.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51056-akron-childrens-hospital-arrhythmia-tachycardia-cryoablation
Dendreon Corporation (Nasdaq: DNDN) announced significant milestones that support broad availability for on-label use of PROVENGE® (sipuleucel-T), the first autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic castrate resistant (hormone refractory) prostate cancer (mCRPC).
To view Multimedia News Release, go to http://www.multivu.com/mnr/50924-dendreon-provenge-cellular-immunotherapy
Today from 7 a.m. to 12 p.m. (Pacific Time-US), surgeons from the Swedish Orthopedic Institute will offer people the opportunity to see a knee surgery in a way that has rarely been done before by a health-care system. Sean Toomey, M.D., an orthopedic surgeon, will repair the knee of a 70-year-old male patient, while it is streamed live online. The webcast will be moderated by orthopedic surgeon James Crutcher, M.D. The patient, identified by Dr. Toomey as a candidate for a partial knee replacement procedure, volunteered and consented to have his minimally invasive knee resurfacing surgery streamed on the Internet.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/swedish/49172/
